KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Current Deferred Revenue (2017 - 2025)

Neogenomics (NEO) has disclosed Current Deferred Revenue for 9 consecutive years, with $851000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue rose 108.07% year-over-year to $851000.0, compared with a TTM value of $851000.0 through Dec 2025, up 108.07%, and an annual FY2025 reading of $851000.0, up 108.07% over the prior year.
  • Current Deferred Revenue was $851000.0 for Q4 2025 at Neogenomics, down from $2.1 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $7.6 million in Q4 2022 and bottomed at $409000.0 in Q4 2024.
  • Average Current Deferred Revenue over 5 years is $3.2 million, with a median of $2.1 million recorded in 2023.
  • The sharpest move saw Current Deferred Revenue crashed 83.72% in 2024, then soared 253.65% in 2025.
  • Year by year, Current Deferred Revenue stood at $5.2 million in 2021, then soared by 45.92% to $7.6 million in 2022, then crashed by 71.88% to $2.1 million in 2023, then tumbled by 80.8% to $409000.0 in 2024, then soared by 108.07% to $851000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for NEO at $851000.0 in Q4 2025, $2.1 million in Q3 2025, and $1.5 million in Q2 2025.